Autoimmune myelofibrosis (AIMF) plays a role in the development of cytopenias in patients with autoimmune disorders, according to a small study involving 12 individuals. Improvement occurred with immunosuppressive therapy. Investigators conducted a single-institution, retrospective chart review of patients with AIMF, looking at clinical presentations, therapies, and outcomes. Among the results:

• All patients had detectable autoantibodies; most had concomitant autoimmune disorders.
• Immunosuppresive therapy led to complete response of cytopenias in 4 patients and partial response in 3.
• Partial response occurred in 1 patient post-splenectomy.
• No myeloproliferative neoplasms were seen during a median follow-up of ~6 years.